Compare

QIAGEN N.V./$QGEN

1D1W1M3M6MYTD1Y5YMAX

About QIAGEN N.V.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Ticker
$QGEN
Sector
Health
Primary listing
NYSE
Employees
5,500
Headquarters
Venlo, Netherlands
Website
www.qiagen.com

QIAGEN N.V. Metrics

BasicAdvanced
$11B
26.47
$1.92
0.56
$0.35
0.69%

What the Analysts think about QIAGEN N.V.

Analyst ratings (Buy, Hold, Sell) for QIAGEN N.V. stock.
Analyst projections of the future price of QIAGEN N.V. stock.

Bulls say / Bears say

QIAGEN beat its Q2 outlook, with adjusted earnings per share of $0.62 and a 29.4% adjusted operating margin. This shows it can preserve profitability even while sales growth is modest. (QIAGEN)
New automated sample-preparation systems extend QIAGEN’s offer from small to high-throughput laboratories. The QIAmini launch targets more than 100,000 potential placements and can cut hands-on processing time by over 80%, creating scope to grow instrument use and recurring kit sales. (QIAGEN, QIAGEN)
QIAcuity’s digital PCR sales grew at a double-digit rate in Q2, and QIAGEN is broadening the platform’s assay menu and automation. More applications could help drive further instrument adoption and sales of associated consumables. (QIAGEN, QIAGEN)
QIAGEN cut its 2026 sales-growth outlook from at least 5% to 1–2% at constant exchange rates. Lower immigration-related QuantiFERON testing and cautious US life-sciences spending are weighing on demand. (QIAGEN)
Q2 sales were flat year on year, while instrument sales fell at a low double-digit rate as US life-sciences customers remained cautious about capital spending. That softness could limit recovery even as consumables and selected growth areas hold up. (QIAGEN, QIAGEN SEC Filing - Form 6-K)
Performance is uneven across diagnostic products: QIAstat-Dx sales fell 7% and PCR and nucleic-acid amplification sales fell 8% in Q2 at constant exchange rates. Lower respiratory testing and weaker OEM demand show that growth in QIAcuity has not yet lifted these lines overall. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

QIAGEN N.V. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

QIAGEN N.V. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

QIAGEN N.V. News

AllArticlesVideos

This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Benzinga2 weeks ago

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

Business Wire2 weeks ago

QIAGEN reports preliminary Q3 2026 results

Business Wire2 weeks ago

Funds containing QIAGEN N.V.

AllEURUSD
Funds
Fund name
Fund size
$QGEN weighting
Xtrackers DAX£XDAX
€7.3B0.52%
HSBC MSCI Europe Islamic Screened$HIEU
€144M0.33%
HSBC MSCI Europe Islamic Screened£HIPS
€144M0.33%
SPDR MSCI World Health Care$WHEA
$708M0.12%
SPDR MSCI World Health Care£HEAW
$708M0.12%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.